Trial Profile
An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy Remark: According to Version V02_0 of the Protocol, Patients May Also be Eligible if EGFR TKI-treatment naïve, EGFR p.T790M-negative at Progression While on EGFR TKI Therapy or After Progression While on Osimertinib Treatment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Nazartinib (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms EATON
- 14 Feb 2024 Status changed from recruiting to completed.
- 02 Nov 2022 Planned primary completion date changed from 15 Sep 2022 to 15 Dec 2022.
- 15 Jun 2022 Planned End Date changed from 25 Nov 2021 to 25 Apr 2023.